Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TranS1's two-level spinal fusion product:

This article was originally published in Clinica

Executive Summary

TranS1 has received US FDA 510(k) clearance for its AxiaLIF 2L two-level percutaneous lumbar fusion system. The Wilmington, North Carolina company's AxiaLIF (axial lumbar interbody fusion) single-level approach was cleared by the FDA in 2004. The older product allows surgeons to access the L5-S1 vertebrae via a one-inch (2.54cm) opening, while AxiaLIF 2L is designed to treat degenerative disc disease at both the L5-S1 and L4-L5 lumbar discs through a single 1.5 inch (3.81cm) incision. TranS1 said there were similar advantages with both minimally-invasive procedures - early release from hospital, rapid return to normal activities and long-term reduction of leg and back pain. AxiaLIF 2L is already available in Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel